Literature DB >> 23974192

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

Arian van der Veer1, Esmé Waanders, Rob Pieters, Marieke E Willemse, Simon V Van Reijmersdal, Lisa J Russell, Christine J Harrison, William E Evans, Vincent H J van der Velden, Peter M Hoogerbrugge, Frank Van Leeuwen, Gabriele Escherich, Martin A Horstmann, Leila Mohammadi Khankahdani, Dimitris Rizopoulos, Hester A De Groot-Kruseman, Edwin Sonneveld, Roland P Kuiper, Monique L Den Boer.   

Abstract

Most relapses in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) are not predicted using current prognostic features. Here, we determined the co-occurrence and independent prognostic relevance of 3 recently identified prognostic features: BCR-ABL1-like gene signature, deletions in IKZF1, and high CRLF2 messenger RNA expression (CRLF2-high). These features were determined in 4 trials representing 1128 children with ALL: DCOG ALL-8, ALL9, ALL10, and Cooperative ALL (COALL)-97/03. BCR-ABL1-like, IKZF1-deleted, and CRLF2-high cases constitute 33.7% of BCR-ABL1-negative, MLL wild-type BCP-ALL cases, of which BCR-ABL1-like and IKZF1 deletion (co)occurred most frequently. Higher cumulative incidence of relapse was found for BCR-ABL1-like and IKZF1-deleted, but not CRLF2-high, cases relative to remaining BCP-ALL cases, reflecting the observations in each of the cohorts analyzed separately. No relapses occurred among cases with CRLF2-high as single feature, whereas 62.9% of all relapses in BCR-ABL1-negative, MLL wild-type BCP-ALL occurred in cases with BCR-ABL1-like signature and/or IKZF1 deletion. Both the BCR-ABL1-like signature and IKZF1 deletions were prognostic features independent of conventional prognostic markers in a multivariate model, and both remained prognostic among cases with intermediate minimal residual disease. The BCR-ABL1-like signature and an IKZF1 deletion, but not CRLF2-high, are prognostic factors and are clinically of importance to identify high-risk patients who require more intensive and/or alternative therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23974192      PMCID: PMC3795461          DOI: 10.1182/blood-2012-10-462358

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Ikaros in immune receptor signaling, lymphocyte differentiation, and function.

Authors:  Matthias Merkenschlager
Journal:  FEBS Lett       Date:  2010-10-02       Impact factor: 4.124

2.  Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.

Authors:  Andishe Attarbaschi; Maria Morak; Gunnar Cario; Giovanni Cazzaniga; Hannah M Ensor; Truus te Kronnie; Jutta Bradtke; Georg Mann; Elena Vendramini; Chiara Palmi; Claire Schwab; Lisa J Russell; Martin Schrappe; Valentino Conter; Christopher D Mitchell; Sabine Strehl; Martin Zimmermann; Ulrike Pötschger; Christine J Harrison; Martin Stanulla; Renate Panzer-Grümayer; Oskar A Haas; Anthony V Moorman
Journal:  Br J Haematol       Date:  2012-07-23       Impact factor: 6.998

3.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

Authors:  R P Kuiper; E Waanders; V H J van der Velden; S V van Reijmersdal; R Venkatachalam; B Scheijen; E Sonneveld; J J M van Dongen; A J P Veerman; F N van Leeuwen; A Geurts van Kessel; P M Hoogerbrugge
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

4.  Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.

Authors:  C Virely; S Moulin; C Cobaleda; C Lasgi; A Alberdi; J Soulier; F Sigaux; S Chan; P Kastner; J Ghysdael
Journal:  Leukemia       Date:  2010-04-15       Impact factor: 11.528

5.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

6.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

Authors:  Richard C Harvey; Charles G Mullighan; Xuefei Wang; Kevin K Dobbin; George S Davidson; Edward J Bedrick; I-Ming Chen; Susan R Atlas; Huining Kang; Kerem Ar; Carla S Wilson; Walker Wharton; Maurice Murphy; Meenakshi Devidas; Andrew J Carroll; Michael J Borowitz; W Paul Bowman; James R Downing; Mary Relling; Jun Yang; Deepa Bhojwani; William L Carroll; Bruce Camitta; Gregory H Reaman; Malcolm Smith; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

7.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Charles G Mullighan; I-Ming Chen; Walker Wharton; Fady M Mikhail; Andrew J Carroll; Huining Kang; Wei Liu; Kevin K Dobbin; Malcolm A Smith; William L Carroll; Meenakshi Devidas; W Paul Bowman; Bruce M Camitta; Gregory H Reaman; Stephen P Hunger; James R Downing; Cheryl L Willman
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

8.  Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; J Racquel Collins-Underwood; Letha A A Phillips; Michael G Loudin; Wei Liu; Jinghui Zhang; Jing Ma; Elaine Coustan-Smith; Richard C Harvey; Cheryl L Willman; Fady M Mikhail; Julia Meyer; Andrew J Carroll; Richard T Williams; Jinjun Cheng; Nyla A Heerema; Giuseppe Basso; Andrea Pession; Ching-Hon Pui; Susana C Raimondi; Stephen P Hunger; James R Downing; William L Carroll; Karen R Rabin
Journal:  Nat Genet       Date:  2009-10-18       Impact factor: 38.330

9.  MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.

Authors:  Vincent H J van der Velden; Jacques J M van Dongen
Journal:  Methods Mol Biol       Date:  2009

10.  Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.

Authors:  Mignon L Loh; Jinghui Zhang; Richard C Harvey; Kathryn Roberts; Debbie Payne-Turner; Huining Kang; Gang Wu; Xiang Chen; Jared Becksfort; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Brent Wood; Michael J Borowitz; Meenakshi Devidas; Daniela S Gerhard; Paul Bowman; Eric Larsen; Naomi Winick; Elizabeth Raetz; Malcolm Smith; James R Downing; Cheryl L Willman; Charles G Mullighan; Stephen P Hunger
Journal:  Blood       Date:  2012-12-04       Impact factor: 22.113

View more
  112 in total

1.  Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.

Authors:  Marieke H van der Linden; Judith M Boer; Pauline Schneider; Merel Willekes; Lidija Seslija; Paola De Lorenzo; Maria Grazia Valsecchi; Giovanni Cazzaniga; Andrea Biondi; Monique L den Boer; Rob Pieters; Ronald W Stam
Journal:  Haematologica       Date:  2015-12-17       Impact factor: 9.941

Review 2.  Pediatric-like therapy for adults with ALL.

Authors:  Hervé Dombret; Thomas Cluzeau; Françoise Huguet; Nicolas Boissel
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

3.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Authors:  Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

Review 4.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 5.  Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Emily B Heikamp; Ching-Hon Pui
Journal:  J Pediatr       Date:  2018-09-10       Impact factor: 4.406

6.  Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.

Authors:  Setareh Safavi; Markus Hansson; Karin Karlsson; Andrea Biloglav; Bertil Johansson; Kajsa Paulsson
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

7.  Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Cristina Bugarin; Jolanda Sarno; Chiara Palmi; Angela Maria Savino; Geertruy te Kronnie; Michael Dworzak; Angela Shumich; Barbara Buldini; Oscar Maglia; Simona Sala; Ilaria Bronzini; Jean-Pierre Bourquin; Ester Mejstrikova; Ondrej Hrusak; Drorit Luria; Giuseppe Basso; Shai Izraeli; Andrea Biondi; Giovanni Cazzaniga; Giuseppe Gaipa
Journal:  Haematologica       Date:  2015-04-10       Impact factor: 9.941

Review 8.  Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui
Journal:  Front Med       Date:  2014-12-15       Impact factor: 4.592

9.  BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.

Authors:  Judith M Boer; João R M Marchante; William E Evans; Martin A Horstmann; Gabriele Escherich; Rob Pieters; Monique L Den Boer
Journal:  Haematologica       Date:  2015-06-04       Impact factor: 9.941

10.  Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.

Authors:  Tobias Herold; Stephanie Schneider; Klaus H Metzeler; Martin Neumann; Luise Hartmann; Kathryn G Roberts; Nikola P Konstandin; Philipp A Greif; Kathrin Bräundl; Bianka Ksienzyk; Natalia Huk; Irene Schneider; Evelyn Zellmeier; Vindi Jurinovic; Ulrich Mansmann; Wolfgang Hiddemann; Charles G Mullighan; Stefan K Bohlander; Karsten Spiekermann; Dieter Hoelzer; Monika Brüggemann; Claudia D Baldus; Martin Dreyling; Nicola Gökbuget
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.